
SII, DNDi in pact to develop affordable dengue treatment
New Delhi, June 13 (UNI) The Serum Institute of India (SII), the world’s largest vaccine manufacturer and Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research entity, have entered into a partnership with an aim to accelerate the development of a monoclonal antibody treatment for dengue fever. The initiative specifically targets low- and middle-income countries…